The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Page 20

More JCP Articles

JCP
Delirium and Mortality in COVID-19 Patients
Original Research

August 21, 2023

COVID-19 patients with early onset delirium had a 2-fold increased mortality risk—both in-hospital and after discharge—than those without delirium.
, , , et al
JCP
Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression
Brief Report

August 16, 2023

In this exploratory analysis, 54% of TRD patients receiving nitrous oxide had a reduction in suicidal ideation, compared with 12% in the placebo group.
, , , et al
JCP
Adjunctive Cariprazine for MDD With Inadequate Response to Antidepressants
Original Research

August 16, 2023

This study assessed the efficacy of adjunctive use of cariprazine, an atypical antipsychotic, in MDD patients with inadequate response to antidepressants.
, , , et al
JCP
Developments in Major Depressive Disorder Therapy
Educational Activity

August 14, 2023

Among the greatest unmet needs in MDD is for effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, alternatives…
JCP
Evolving Research on Postpartum Depression Pathophysiology and Treatment
Educational Activity

August 14, 2023

Research on neuroactive steroids reveals their role in perinatal depression, leading to development of novel therapeutics. These emerging treatments hold promise for faster onset and lasting effects.  
,
JCP
Emerging Therapies for Attention-Deficit/Hyperactivity Disorder
Educational Activity

August 9, 2023

While patients with ADHD today still face numerous unmet needs, a number of newer pharmacologic agents and devices with potential advantages over traditional therapies have emerged and gained regulatory…
JCP
Fiscal Impact of Schizophrenia From a Government Perspective
Original Research

August 9, 2023

This analysis revealed that the lifetime fiscal loss to the government was $1,540,042 for each person with schizophrenia.
, , , et al
JCP
Emerging Perspectives in Addiction Psychiatry
Educational Activity

August 9, 2023

FDA-approved medications and early intervention for people with substance use disorders should be encouraged as early as possible to optimize patient outcomes and life expectancy.
JCP
Using Percentiles to Understand Standardized Mean Difference as a Measure of Effect Size
Clinical and Practical Psychopharmacology

August 7, 2023

Chittaranjan Andrade, MD, explains the use of SMDs as a measure of effect size. A recent meta-analysis of the effect of ChEIs on hallucinations and delusions in Alzheimer and…
JCP
Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management
Educational Activity

August 7, 2023

Next generation therapeutics that work well, are better tolerated, and lead to improved outcomes may offer a different treatment approach for patients with schizophrenia.
,
JCP
Antihypertensive Medications and PTSD
Original Research

August 2, 2023

Calcium channel blockers were linked to decreased incidence of PTSD; the association was not found for any other antihypertensive medication classes.
, , , et al
JCP
Hepatitis C Screening and Treatment in Psychiatry Inpatients
Original Research

July 31, 2023

Of people admitted to a psychiatric unit, 4.9% had a positive HCV antibody screening result, underlining the need to screen psychiatric inpatients for hepatitis C.
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe